FAQ

NSC 363812

Known as: NSC-363812 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1988-1999
01219881999

Related topics

Related topics

1 relation

Broader (1)

ormaplatin

Related mentions per year

Related mentions per year

1986-2018
19801990200020102020
NSC 363812
ormaplatin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812)
Ormaplatin (NSC 363812, tetraplatin) is a stable platinum (IV) analog which has exhibited activity against cisplatin-resistant… (More)
  • table 1
  • table 2
  • table 3
  • figure 2
  • figure 1
Is this relevant?
1994
1994
Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
Ormaplatin (tetraplatin, NSC 363812) is a platinum(IV) analogue that is active against cisplatin-resistant cell lines in… (More)
  • figure 1
  • table 1
  • table 3
  • table 2
  • figure 2
Is this relevant?
1994
1994
Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812).
Ormaplatin is a platinum analog that was developed because of an altered toxicity profile and non-cross resistance to cisplatin… (More)
Is this relevant?
1988
1988
Comparative toxicity and renal distribution of the platinum analogs tetraplatin, CHIP, and cisplatin at equimolar doses in the Fischer 344 rat.
Tetraplatin [tetrachloro(dl-trans)1,2-diaminocyclohexane platinum(IV), NSC-363812] is a new anticancer platinum drug analog… (More)
Is this relevant?